申请人:Glaxo Group Limited
公开号:US04985427A1
公开(公告)日:1991-01-15
Compounds of formula (I) ##STR1## wherein R.sup.1 is selected from the group consisting of hydrogen, halogen, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, phenylC.sub.1-3 alkoxy (in which the phenyl group is optionally substituted by a substituent selected from halogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy and hydroxy), nitro, trifluoromethyl, cyano, --CO.sub.2 R.sup.3 (wherein R.sup.3 is selected from hydrogen and C.sub.1-4 alkyl) and --CONR.sup.4 R.sup.5 (wherein R.sup.4 and R.sup.5 are each independently selected from hydrogen and C.sub.1-4 alkyl, or R.sup.4 and R.sup.5 together with the nitrogen atom to which they are attached form a saturated 5- to 7- membered ring, which ring optionally contains one or more groups or atoms selected from oxygen, sulphur, --NH-- and --N(CH.sub.3)--); and R.sup.2 is selected from the group consisting of hydrogen, halogen, hydroxy, C.sub.1-6 alkyl and C.sub.1-6 alkoxy; and salts thereof are inhibitors of the enzyme 5-lipoxygenase. Processes for preparing the compounds of formula (I) and compositions containing them are also described.
公式(I)的化合物##STR1##,其中R.sup.1选自包括氢、卤素、羟基、C.sub.1-6烷基、C.sub.1-6烷氧基、苯基C.sub.1-3烷氧基(其中苯基可被选自卤素、C.sub.1-3烷基、C.sub.1-3烷氧基和羟基的取代基所取代)、硝基、三氟甲基、氰基、--CO.sub.2 R.sup.3(其中R.sup.3选自氢和C.sub.1-4烷基)和--CONR.sup.4 R.sup.5(其中R.sup.4和R.sup.5各自独立地选自氢和C.sub.1-4烷基,或者R.sup.4和R.sup.5与它们所连接的氮原子一起形成一个饱和的5至7元环,该环可选地包含一个或多个选自氧、硫、--NH--和--N(CH.sub.3)--的基团或原子);R.sup.2选自包括氢、卤素、羟基、C.sub.1-6烷基和C.sub.1-6烷氧基的组;及其盐是5-脂氧合酶酶的抑制剂。还描述了制备公式(I)的化合物和包含它们的组合物的方法。